ESC 365 - Intravenous antazoline for cardioversion of recent onset atrial fibrillation in patients with stable coronary artery disease.

EHRA Premium Access

Intravenous antazoline for cardioversion of recent onset atrial fibrillation in patients with stable coronary artery disease.

Session: Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs

Topic: Antiarrhythmic drugs (Atrial Fibrillation)

Speaker: Associate Professor M. Farkowski (Warsaw, PL)

Event: EHRA EUROPACE - CARDIOSTIM 2017

Congress Presentation

Add to my library

About the speaker

Associate Professor Michal Farkowski

Ministry of Interior and Administration National Medical Institute, Warsaw (Poland)

0 follower

6 more presentations in this session

Vernakalant versus ibutilide for immediate conversion of recent-onset Atrial Fibrillation

Speaker: Doctor I. Vogiatzis (Veria, GR)

Impact of gender: rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study

Comparison of local activation time annotation algorithms in high density mapping of regular atrial tachycardias

Speaker: Professor J. De Pooter (Gent, BE)

Higher persistence but lower compliance with direct oral anticoagulants treatment for atrial fibrillation following a personalized therapeutic information: paradoxical results of the MONACO study

Speaker: Professor J. Davy (Montpellier, FR)

A real-world comparison of vernakalant efficacy and safety for pharmacological cardioversion in patients with recent-onset atrial fibrillation in an emergency department and after cardiac surgery.

Speaker: Doctor J. Osca Asensi (Valencia, ES)

Access the full session

Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs

Speakers: Associate Professor M. Farkowski, Doctor I. Vogiatzis, Professor J. De Pooter, Professor J. Davy, Doctor J. Osca Asensi

About the event

EHRA EUROPACE - CARDIOSTIM 2017

18 June - 21 June 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources